A lipid switch unlocks Parkinson's disease-associated ATP13A2
about
Unlocking ATP13A2/PARK9 activityNew Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders.Endolysosomal dysfunction in Parkinson's disease: Recent developments and future challenges.Impulse control disorder, lysosomal malfunction and ATP13A2 insufficiency in Parkinsonism.Prelysosomal Compartments in the Unconventional Secretion of Amyloidogenic Seeds.PI5P and PI(3,5)P2: Minor, but Essential Phosphoinositides.Protection against Mitochondrial and Metal Toxicity Depends on Functional Lipid Binding Sites in ATP13A2.Inhibition of the Formation of the Spf1p Phosphoenzyme by Ca2.Mitophagy in Parkinson's Disease: Pathogenic and Therapeutic Implications.ATP13A2/PARK9 regulates endo-/lysosomal cargo sorting and proteostasis through a novel PI(3, 5)P2-mediated scaffolding function.Phospholipid flippase ATP11C is endocytosed and downregulated following Ca2+-mediated protein kinase C activation.Simultaneous lipidomic and transcriptomic profiling in mouse brain punches of acute epileptic seizure model compared to controls.Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).Atp13a2 Deficiency Aggravates Astrocyte-Mediated Neuroinflammation via NLRP3 Inflammasome Activation.Parkinson disease related ATP13A2 evolved early in animal evolution.Structure/activity relationship of thapsigargin inhibition on the purified Golgi/secretory pathway Ca2+/Mn2+-transport ATPase (SPCA1a).Overlapping expression patterns and functions of three paralogous P5B ATPases in Caenorhabditis elegans.
P2860
Q28118908-0033A04D-3356-4224-AC25-1048E3F0B914Q33783000-00969690-DA86-4769-AD5D-C8463716AF52Q38822081-8E964A3D-26E8-42B4-950E-FF36AF4788FBQ39044609-2CFD8251-90F2-4635-976B-34B300D1AF3FQ39104462-60C33224-5333-4F2A-BD9A-9746DA7E869CQ39182894-DE394EFC-0F61-4F65-BB19-7B2F740243A1Q39706189-1F59C007-7C32-419C-BE68-635CE3A56268Q39771085-65523D1D-63E6-4A9D-8D0A-BF5082D1D993Q42372932-40921065-2E47-4E86-9494-49116651A2B5Q45865997-7429C042-9A92-4B15-95E1-4F3C500243BAQ47171543-166B55DB-C8B1-4CB2-8A87-87CDBC960157Q47363203-C60810F6-399B-4671-831E-26568EC618A1Q47813940-91548F1C-C54E-4B0F-8407-AE31E382D155Q48925750-873E5E23-AC07-4EEC-B7CD-F1291828729CQ50418431-6AA3251B-99C8-476A-85C4-CD1F30072B19Q51109136-F2E58C90-8FA7-4269-82E1-EC182E60B00AQ52430850-90A0D9EA-7818-4604-8B32-490F78C4A20D
P2860
A lipid switch unlocks Parkinson's disease-associated ATP13A2
description
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
article publié dans les Procee ...... f the United States of America
@fr
artículu científicu espublizáu en 2015
@ast
im Juli 2015 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2015/07/21)
@sk
vědecký článek publikovaný v roce 2015
@cs
wetenschappelijk artikel (gepubliceerd op 2015/07/21)
@nl
наукова стаття, опублікована в липні 2015
@uk
name
A lipid switch unlocks Parkinson's disease-associated ATP13A2
@ast
A lipid switch unlocks Parkinson's disease-associated ATP13A2
@en
A lipid switch unlocks Parkinson's disease-associated ATP13A2
@nl
type
label
A lipid switch unlocks Parkinson's disease-associated ATP13A2
@ast
A lipid switch unlocks Parkinson's disease-associated ATP13A2
@en
A lipid switch unlocks Parkinson's disease-associated ATP13A2
@nl
prefLabel
A lipid switch unlocks Parkinson's disease-associated ATP13A2
@ast
A lipid switch unlocks Parkinson's disease-associated ATP13A2
@en
A lipid switch unlocks Parkinson's disease-associated ATP13A2
@nl
P2093
P2860
P50
P921
P356
P1476
A lipid switch unlocks Parkinson's disease-associated ATP13A2
@en
P2093
Chris Van den Haute
Danny Mollerup Sørensen
Diane Hermans
Frank Wuytack
Jan Eggermont
Shaun Martin
Tine Holemans
P2860
P304
P356
10.1073/PNAS.1508220112
P407
P50
P5008
P577
2015-07-21T00:00:00Z